A phase I study of ICT01-2588 for the treatment for solid and hematologic malignancies
Latest Information Update: 02 Aug 2019
At a glance
- Drugs ICT01 2588 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- 01 Aug 2019 According to a ImCheck Therapeutics media release, start of clinical development of ICT01 during the first quarter of 2020, followed by a combination study with anti-PD-1/L1 antibodies.
- 27 Jul 2016 New trial record